This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res. 2009;69:3121–30.
Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111:865–73.
Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, et al. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018;215:681–97.
Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager, SL, Call TG, et al. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178:99–105.
Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood. 2013;122:3317–21.
Riches JC, O’Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014;123:4101–10.
Thompson PA, Ferrajoli A, O’Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2015;170:125–8.
De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev. 2012;247:73–92.
Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood 2013;122:2848–55.
Ma S, Shukla V, Fang L, Gould KA, Joshi SS, Lu R. Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4. J Biol Chem. 2013;288:26430–40.
Simonetti G, Carette A, Silva K, Wang H, De Silva NS, Heise N, et al. IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity. J Exp Med. 2013;210:2887–902.
Ma H, Qazi S, Ozer Z, Zhang J, Ishkhanian R, Uckun FM. Regulatory Phosphorylation of Ikaros by Bruton’s Tyrosine Kinase. PLoS ONE 2013;8:e71302.
Hagner PR, Man H-W, Fontanillo C, Wang M, Couto S, Breider M, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood 2015;126:779–89.
Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, et al. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia. 2018;32:654–62.
Schwickert TA, Tagoh H, Gültekin S, Dakic A, Axelsson E, Minnich M, et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat Immunol. 2014;15:283–93.
Acknowledgements
Funding
This work was supported by Associazione Italiana per la Ricerca sul Cancro and Fondazione Cariplo (TRIDEO 16923 to R M), AIRC IG14376 and PRIN 2015 ZMRFEA_002 (to RM). SF was supported by FIRC/AIRC Triennal Fellowship 16430, Milan, Italy and now by Fondazione Umberto Veronesi, Milan, Italy; Ricerca Finalizzata Giovani Ricercatori 2011–2012, Ministero della Salute (GR-2011-02349282 to RM) (GR-2011-02346826 to AZ), Rome, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author contributions
RM and SF conceived the research, coordinated the research, and interpreted the results; SF analyzed the results and wrote the manuscript; SF performed the in vitro experiments; SF acquired and analyzed flow cytometric data; SB and PZ performed some molecular analyses; SF performed the statistical analyses; AZ provided protein samples for some western blot evaluation; RM supervised the workflow, and revised the results and the manuscript critically. VG, ML, and RM revised and approved the final version of the paper.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Fiorcari, S., Benatti, S., Zucchetto, A. et al. Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. Leukemia 33, 1278–1302 (2019). https://doi.org/10.1038/s41375-018-0296-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0296-5
This article is cited by
-
The dynamic functions of IRF4 in B cell malignancies
Clinical and Experimental Medicine (2022)
-
IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK
Leukemia (2021)